Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04353414 · ClinicalTrials.gov registry record · Phase 4
Transmuscular Quadratus Lumborum Block Plus Pericapsular Injection vs Pericapsular Injection
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 104
- Enrollment target
NCT04353414 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 104 participants.
The verdict
NCT04353414, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 104 participants
- Enrollment target
Study Summary
The purpose of this research study is to compare two different treatment options on their effectiveness to reduce post-operative pain, narcotic (opioid pain medication) usage and recovery time in patients undergoing primary hip arthroscopy surgery. The first treatment option is a Transmuscular Quadratus Lumborum (TQL) block plus hip incision site (Pericapsular) Injection. The TQL block is an ultrasound guided injection between the quadratus lumborum and the psoas muscles in the back. The anesthesiologist will perform the TQL block The second treatment option is only a hip incision site (Pericapsular) Injection. In this group, the surgeon will inject local anesthetic into the incision or hip portal sites to decrease sensation.
Interventions
- DRUG Bupivacaine Hydrochloride
- PROCEDURE Pericapsular injection
- PROCEDURE Transmuscular Quadratus Lumborum Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2022-02-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04353414
The ClinicalTrials.gov registry entry for NCT04353414 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bupivacaine Hydrochloride is the first listed.
NCT04353414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04353414 about?
NCT04353414 is a clinical study titled "Transmuscular Quadratus Lumborum Block Plus Pericapsular Injection vs Pericapsular Injection". The purpose of this research study is to compare two different treatment options on their effectiveness to reduce post-operative pain, narcotic (opioid pain medication) usage and recovery time in patients undergoing primary hip arthroscopy surgery. The first treatment option is a Transmuscular Quad...
What is the current status of trial NCT04353414?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 104 participants. The study started on 2020-08-01. Estimated completion is 2022-02-23.
What interventions are being tested in trial NCT04353414?
The interventions under investigation include: Bupivacaine Hydrochloride (DRUG), Pericapsular injection (PROCEDURE), Transmuscular Quadratus Lumborum Block (PROCEDURE).
Who is sponsoring clinical trial NCT04353414?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.